HomeInsightsStock Comparison

Bliss Gvs Pharma Ltd vs Cohance Lifesciences Ltd Stock Comparison

Bliss Gvs Pharma Ltd vs Cohance Lifesciences Ltd Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

  • The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 267.45 as of 06 May 15:30 . The P/E Ratio of Bliss GVS Pharma Ltd changed from 14.9 on March 2021 to 14.7 on March 2025 . This represents a CAGR of -0.27% over 5 yearsThe P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 years The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1018 crore on March 2021 to ₹ 1238 crore on March 2025 . This represents a CAGR of 4.00% over 5 yearsThe Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 years The revenue of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 236.71 crore as compare to the Sep '25 revenue of ₹ 252.86 crore. This represent the decline of -6.39% The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The ebitda of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 50.73 crore as compare to the Sep '25 ebitda of ₹ 51.94 crore. This represent the decline of -2.33% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The net profit of Bliss GVS Pharma Ltd changed from ₹ 22.11 crore to ₹ 24.78 crore over 7 quarters. This represents a CAGR of 6.73% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The Dividend Payout of Bliss GVS Pharma Ltd changed from 7.64 % on March 2021 to 7.64 % on March 2025 . This represents a CAGR of 0.00% over 5 yearsThe Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Bliss GVS Pharma Ltd

  • Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
  • The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
  • The Company has its manufacturing facility at Palghar which is WHO GMP approved.
  • The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards. The company commenced its business in 1985.
  • In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

About Cohance Lifesciences Ltd

  • Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
  • The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
  • May 7, 2025.
  • Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

FAQs for the comparison of Bliss GVS Pharma Ltd and Cohance Lifesciences Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Cohance Lifesciences Ltd?

Market cap of Bliss GVS Pharma Ltd is 2,829 Cr while Market cap of Cohance Lifesciences Ltd is 18,399 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Cohance Lifesciences Ltd?

The stock performance of Bliss GVS Pharma Ltd and Cohance Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Cohance Lifesciences Ltd?

As of May 6, 2026, the Bliss GVS Pharma Ltd stock price is INR ₹267.45. On the other hand, Cohance Lifesciences Ltd stock price is INR ₹480.95.

How do dividend payouts of Bliss GVS Pharma Ltd and Cohance Lifesciences Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Cohance Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions